Eczema Cream for the Face: What Tacrolimus Versus Fluticasone Actually Showed
The hero image is an AI-created illustration of fictional facial dermatitis-like dryness, not a study participant, a diagnostic example or a result from Dr. Arsy #003.
Searching for an eczema cream for the face often brings up several prescription names with little explanation of their differences. One trial compared two actual medicines directly in adults with facial atopic dermatitis. Its response rates are useful, provided “response” is not mistaken for complete clearance or a guarantee for every face.
Who was studied, and why that matters
The primary 2009 randomized trial enrolled 568 adults with moderate-to-severe atopic dermatitis of the face whose conventional treatment had been ineffective or poorly tolerated. Participants received tacrolimus 0.1% ointment, 288 people, or fluticasone 0.005% ointment, 280 people. Treatment was double-blind and twice daily for three weeks or until clearance.
These were ointments, even though many people use the phrase “face eczema cream” when searching. The results cannot be assigned to every formulation containing either ingredient, to over-the-counter hydrocortisone or to cosmetic moisturizers. They also do not describe a study in infants or a first episode of an undiagnosed facial rash.
93% versus 88% described a score threshold
The main endpoint was at least a 60% reduction in the modified Local Eczema and Severity Index, or mLEASI, at day 21. That threshold measures improvement in a local eczema score. It is not the same as completely clear skin.
| Reported day-21 result | Tacrolimus 0.1% ointment | Fluticasone 0.005% ointment |
|---|---|---|
| At least 60% mLEASI improvement | 93% | 88% |
| Global response rated marked improvement or better | 88% | 79% |
| Switch to the other medicine at day 21 | 4.5% | 9% |
The primary response difference was statistically significant, p=0.026. The rounded percentages imply an approximately five-percentage-point difference, not a 93% advantage over the comparator. Both treatments improved facial redness and itch. The accessible primary abstract does not supply a confidence interval for the main comparison, so none is invented here.
The tradeoff included more application-site burning
Adverse events were more frequent with tacrolimus because application-site burning occurred more often. A higher response percentage does not make tolerability irrelevant, especially on facial skin. Ask the prescriber which early sensations can occur, how long to expect them and what worsening or persistent symptoms require review. The study is evidence to discuss, not a reason to borrow someone else’s prescription.
After day 21, participants could stop study treatment, continue the same ointment once daily or switch medicines twice daily according to clearance and satisfaction. This flexible later period should not be presented as though everyone remained in the same fixed three-week comparison indefinitely. The abstract does not establish a universal maintenance schedule or long-term superiority.
Concentration alone cannot choose a facial medicine
The numbers 0.1% and 0.005% do not mean one medicine is simply twenty times stronger. They are different active substances with different actions. Our potency and vehicle guide explains why the ingredient, formulation, body site and instructions belong together.
The current U.S. tacrolimus label describes second-line, short-term and noncontinuous chronic treatment for specified patients with moderate-to-severe atopic dermatitis. Only the lower 0.03% strength is indicated for children aged 2–15. Its boxed warning addresses unestablished long-term safety and rare malignancy reports without an established causal relationship; continuous long-term use should be avoided. The label also advises against ultraviolet therapy and tanning exposure during treatment. Follow the clinician’s facial-area instructions.
Our calcineurin-inhibitor guide and cancer-risk research explanation provide context. Neither substitutes for reviewing the medicine’s warnings and individual suitability.
Make the face-care plan specific
Ask which exact areas need medicine, which product is intended for background dryness, when to reassess and what to do if the rash returns. If the eyelids are involved, request separate instructions rather than assuming every facial treatment belongs near the eyes. Our eyelid and face-cream guide explains that distinction.
Dr. Arsy Moisturizer #003, 4 oz is a cosmetic moisturizer for hydration, moisture-barrier support and ordinary dry-skin comfort. It was not tested in this trial, does not reproduce either medicine’s response rate and is not an eczema treatment. Ask which moisturizer fits your prescribed facial-care plan.
Educational information; primary abstract and current label checked November 9, 2026. No independent clinician review of this article is claimed.